2Lauta VM. A review of the cytokine network in multiple myelo- ma: diagnostic, prognostic, and therapeutic implications[J]. Cancer, 2003,97 (10) : 2440-2452.
3Alexandrakis MG, Passam FJ, Ganotakis E, et al. Bone marrow microvascular density and angiogenic growth {actors in multiple myeloma[J]. Clin Chem Lab Med, 2004,42(10) : 1122-1126.
4Alexandrakis MG, Passam FH, Boula A, ct al. Relationship be- tween circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth Factor and vascular endothelial growth {actor in multiple myeloma[J]. Ann Hema-tol, 2003,82(1) : 19-23.
5Ribatti D. The crucial role of vascular permeability factor/vascu- lar endothelial growth factor in angiogenesis.-a historical review[J]. Br J Haematol,2005,128(3):303-309.
6H uang SY,Chen BB, Lu H Y, et al. Correlation among DCE MRI measurements of bone marrow angiogenesis, mierovessel densi- ty, and extramedullary disease in patients with multiple myeloma [J]. AmJ Hematol,2012,87(8):837-839.
7Ye P,Rodriguez FH,Kanaly S, et al. Requirement of interleukin 17 receptor signaling for lung CXC ehemokine and granulocyte colonystimulating factor expression, neutrophil recruitment, and host defense[J]. J Exp Med, 2001,194(4) :519-527.
8Numasaki M, Fukushi J, Ono M, et al. Interleukin 17 promotes angiogenesis and tumor growth[J]. Blood, 2003,101 (7) : 2620-2627.
9Takahashi H, Numasaki M, Lotze MT, et al. Interleukin 17 en- hances bFGF-, HGF- and VEGF induced growth of vascular en- dothelial cells[J]. Immunol Lett,2005,98(2) : 189-193.
10Wrobel T, Mazur G, Jazwiec B, et al. Interleukin-17 in acute mye loid leukemia[J]. J Cell Mol Med, 2003,7 (4) :472-474.
